Go to Contents
ABOUT US
Company History
Jennerex
Contact Us
TECHNOLOGY
SOLVE ®
GEEV ®
Scientific Publications
PIPELINE
Development Pipeline
Pexa-Vec
(JX-594)
BAL0891
SJ-600 Series
JX-900 Series
PARTNERSHIP
Pexa-Vec
Partnership
IR/PR
Publications & News
Financials
IR Inquiries
SillaJen Biotherapeutics
About SillaJen Biotherapeutics
Contact Us
Sillajen Sitemap
ABOUT US
Company History
Jennerex
Contact Us
TECHNOLOGY
SOLVE ®
GEEV ®
Scientific Publications
PIPELINE
Development Pipeline
Pexa-Vec (JX-594)
BAL0891
SJ-600 Series
JX-900 Series
PARTNERSHIP
Pexa-Vec Partnership
IR/PR
Publications & News
Financials
IR Inquiries
SillaJen Biotherapeutics
About SillaJen Biotherapeutics
Contact Us
ENG
|
KOR
ENG
ENG
KOR
Targeting, Attacking, and Eradicating Cancers®
TOP
IR/PR
ABOUT US
TECHNOLOGY
PIPELINE
PARTNERSHIP
IR/PR
SillaJen Biotherapeutics
Notice & News
Publications & News
Stock Information
Financials
IR Inquiries
Notice & News
게시판
SillaJen to receive 'PD-1 inhibitor' from BeiGene for 'BAL0891' combination clinical trial
2025-01-16
Link address :
https://www.thebionews.net/news/articleView.html?idxno=11930
Targeting, Attacking, and Eradicating Cancers®
